Synonyms: Ms4a1, B1
Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 1 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Ofatumumab (Anti-CD20) is a fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. MW: 145.94 kD.
|
References |
|---|
| CAS No. | 679818-59-8 |
|---|---|
| Molecular Weight | 145.94 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06688331 | RECRUITING | Presymptomatic Diabetes Type 1 (Stage 1); Diabetes Mellitus, Type I; Diabetes Mellitus, Type 1 | PolTREG S.A. | 2025-03-12 | PHASE2 | |
| NCT06824701 | ACTIVE_NOT_RECRUITING | Drug: Zanubrutinib|Drug: Rituximab|Drug: Obinutuzumab | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | University of Utah | 2025-09-12 | PHASE1 |
| NCT07189325 | RECRUITING | Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, | Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy | University Hospital, Montpellier | 2026-06-15 | PHASE3 |
| NCT06149286 | RECRUITING | Drug: Odronextamab|Drug: Lenalidomide|Drug: Rituximab | Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Regeneron Pharmaceuticals | 2023-12-28 | PHASE3 |
| NCT07480863 | ACTIVE_NOT_RECRUITING | Drug: Orelabrutinib|Drug: Zuberitamab|Drug: Cyclophosphamide | Marginal Zone Lymphoma(MZL) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 | PHASE2 |
| NCT06943872 | RECRUITING | Drug: Sonrotoclax|Drug: Obinutuzumab|Drug: Rituximab|Drug: V | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | BeOne Medicines | 2025-06-11 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-07-17)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.